The current AhR-dependent anti-inflammatory active agent (Tapinarof) has been shown to reduce inflammatory cytokine production and improve skin inflammatory symptoms in animal models, and its efficacy and safety in treating mild to severe AD have been confirmed in randomized controlled trials [63]. Here, AHR is linked to Alzheimer disease.